Saturday 17 October 2026
Export COLL’s income statement to Excel — free account
Collegium Pharmaceutical, Inc.
COLL Healthcare Drug Manufacturers Specialty & Generic
Collegium Pharmaceutical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $780.6 million, up 23.6% from fiscal 2024. In the quarter to June 2026, revenue grew 6.32%, EPS fell 221.1%, free cash flow fell 2.14% and total debt rose 32.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
23.19
0.01
+0.04%
Follow COLL
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
7 | 6 | 8 | 4 | 5 | 5 | 5 | 4 | — | — |
P/E ratio |
23.15 | 13.39 | 21.24 | 0.00 | 9.29 | 26.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
1.58 | 0.95 | 1.43 | 0.62 | 0.83 | 1.02 | 1.17 | 1.01 | 6.84 | 5.51 |
P/S ratio |
1.88 | 1.46 | 1.86 | 1.72 | 2.36 | 2.22 | 2.32 | 2.02 | 19.87 | 0.00 |
Altman Z″-Score (non-manufacturers) |
1.76 | 0.42 | 0.99 | (0.46) | (0.26) | (0.28) | (2.78) | (2.68) | (2.50) | 2.22 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.97 | 0.00 | 0.00 |
P/Operating CF |
11.93 | 10.92 | 14.37 | 12.03 | 18.03 | 30.53 | 43.98 | 13.38 | (42.57) | (16.34) |
Beneish M-Score |
(3.32) | (2.52) | (3.54) | (2.30) | (2.42) | (1.76) | (3.19) | 33.95 | 10.27 | — |
P/B ratio |
4.87 | 4.04 | 5.39 | 4.09 | 3.22 | 3.70 | 7.87 | 6.18 | 5.44 | 2.82 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.89 | 11.95 | 5.54 | 2.86 |
EV/Sales |
2.40 | 2.52 | 2.49 | 2.86 | 2.59 | 2.49 | 1.79 | 1.54 | 15.77 | 0.00 |
EV/EBITDA |
4.62 | 4.72 | 4.48 | 7.69 | 8.28 | 6.56 | 0.00 | 4.77 | 0.00 | 0.00 |
EV/Operating CF |
5.68 | 7.75 | 5.13 | 10.67 | 6.92 | 8.22 | 19.08 | 2.54 | (6.70) | (3.08) |
EV/FCF |
(46.03) | (9.64) | (15.01) | (5.39) | (2.69) | (2.76) | (16,561.38) | 3.02 | (6.60) | (3.06) |
Quick Ratio |
1.40 | 0.82 | 1.07 | 0.82 | 1.05 | 1.08 | 1.20 | 1.19 | 4.09 | 6.07 |
Current Ratio |
1.57 | 0.95 | 1.17 | 0.97 | 1.13 | 1.16 | 1.27 | 1.26 | 4.24 | 6.20 |
Net Debt/EBITDA |
1.00 | 1.97 | 1.13 | 3.06 | 0.73 | 0.70 | 19.18 | (1.50) | 1.57 | 1.60 |
Debt/Assets |
48.85% | 51.24% | 58.35% | 59.70% | 36.12% | 39.93% | 3.75% | 3.95% | 1.09% | 2.56% |
Debt/Equity |
2.68 | 3.73 | 3.41 | 3.60 | 1.23 | 1.38 | 0.13 | 0.13 | 0.01 | 0.03 |
Asset Turnover |
0.47 | 0.45 | 0.49 | 0.50 | 0.41 | 0.65 | 0.99 | 1.31 | 0.19 | 0.01 |
Operating CF/Net income |
5.24 | 2.96 | 5.71 | (4.97) | 1.45 | 3.51 | (1.22) | (4.33) | 0.90 | 0.80 |
Capex/Depreciation |
(0.01) | (0.01) | 0.00 | (0.01) | (0.03) | (6.07) | (0.42) | (0.22) | (1.67) | (0.73) |
Interest Coverage |
2.18 | 2.30 | 2.00 | 0.53 | 0.84 | 1.95 | (26.13) | (1.03) | (129.63) | (1,000.87) |
| 23.70% | 32.62% | 24.68% | (12.57%) | 36.77% | 19.57% | (25.39%) | (39.99%) | (62.65%) | (85.62%) | |
| 3.79% | 4.93% | 4.16% | (2.68%) | 10.71% | 5.63% | (7.61%) | (18.33%) | (50.32%) | (72.52%) | |
ROIC |
15.94% | 11.88% | 18.90% | 2.88% | 4.13% | 13.06% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
23.87% | (535.36%) | 50.34% | (432.26%) | 128.93% | 46.59% | (34.53%) | (67.86%) | (72.11%) | (70.27%) |
Average Days of Receivables |
98.82 | 132.10 | 115.61 | 144.07 | 139.54 | 98.10 | 89.75 | 101.46 | 127.78 | 454.17 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.86% | 3.41% | 3.15% | 3.48% | 3.09% | 30.10% | 873.64% |
Selling, General and Administrative Expense of Revenue |
36.49% | 33.31% | 28.09% | 37.11% | 42.97% | 36.72% | 39.25% | 45.20% | 325.73% | 4,712.57% |
Intangible Assets out of Total Assets |
0.49 | 0.63 | 0.49 | 0.60 | 0.39 | 0.52 | 0.10 | 0.15 | 0.00 | 0.01 |
Share Based Compensation of Revenue |
5.37% | 5.13% | 4.79% | 4.93% | 8.76% | 7.07% | 5.57% | 4.91% | 27.90% | 338.22% |
Graham Net Nets |
(0.45) | (1.03) | (0.39) | (0.70) | (0.27) | (0.26) | 0.05 | 0.07 | 0.18 | 0.35 |
Graham Number |
20.69 | 18.48 | 13.84 | 0.00 | 16.21 | 9.68 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
4.32% | 7.47% | 4.71% | (3.12%) | 10.76% | 3.84% | (3.30%) | (6.99%) | (13.37%) | (24.74%) |
Free Cash Flow Yield |
(2.77%) | (17.83%) | (8.91%) | (30.79%) | (40.85%) | (40.60%) | 0.00% | 25.19% | (12.02%) | (19.90%) |
Revenue per Share |
24.62 | 19.57 | 16.80 | 13.71 | 7.92 | 9.01 | 8.87 | 8.51 | 0.94 | 0.07 |
Operating CF per Share |
10.39 | 6.35 | 8.14 | 3.67 | 2.96 | 2.73 | 0.83 | 5.14 | (2.21) | (3.09) |
Capex per Share |
(0.05) | (0.05) | (0.01) | (0.05) | (0.06) | (10.86) | (0.19) | (0.74) | (0.03) | (0.02) |
Free Cash Flow per Share |
10.33 | 6.30 | 8.13 | 3.62 | 2.91 | (8.13) | 0.64 | 4.40 | (2.25) | (3.11) |
Cash per Share |
12.82 | 5.82 | 9.20 | 5.13 | 5.34 | 5.06 | 5.08 | 4.45 | 3.92 | 6.32 |
Shareholders Equity per Share |
9.51 | 7.09 | 5.79 | 5.76 | 5.81 | 5.41 | 2.61 | 2.78 | 3.44 | 5.56 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
9.51 | 7.09 | 5.79 | 5.76 | 5.81 | 5.41 | 2.61 | 2.78 | 3.44 | 5.56 |
Free Cash Flow |
327.58 | 203.33 | 274.29 | 122.61 | 101.61 | (279.83) | 21.35 | 145.04 | (68.01) | (75.53) |
Working Capital |
251.38 | (27.25) | 79.69 | (13.74) | 35.98 | 38.44 | 53.96 | 48.39 | 102.00 | 132.98 |
Capital Expenditures |
(1.74) | (1.65) | (0.46) | (1.62) | (1.94) | (373.77) | (6.44) | (24.35) | (0.99) | (0.48) |
Net Current Asset Value |
(663.75) | (952.49) | (410.28) | (559.30) | (173.61) | (179.92) | 36.85 | 37.85 | 102.00 | 131.47 |
EV/EBIT |
10.41 | 9.36 | 8.45 | 39.77 | 40.63 | 13.73 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 1.21 | 0.02 | 0.09 | 0.03 | 0.28 |
Price to Operating Income |
8.17 | 5.44 | 6.31 | 23.94 | 37.02 | 12.26 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
18.73 | 11.66 | 9.26 | 7.12 | 3.54 | 3.24 | 1.31 | 11.96 | 0.33 | 0.63 |
Cash ROIC |
21.59% | 16.02% | 23.38% | 11.46% | 15.89% | (45.34%) | 7.94% | 58.08% | (30.33%) | (25.84%) |
Accounts Receivable Turnover |
3.55 | 3.09 | 3.13 | 3.21 | 2.93 | 3.97 | 3.93 | 6.38 | 4.71 | 0.28 |
Accounts Payable Turnover |
43.49 | 40.25 | 39.49 | 66.24 | 17.78 | 16.01 | 21.05 | 18.58 | 0.35 | 0.03 |
Inventory Turnover |
8.30 | 7.49 | 6.10 | 7.96 | 7.65 | 10.31 | 22.18 | 34.41 | 1.66 | 0.14 |
Average Days of Payables |
12.26 | 5.65 | 13.19 | 5.01 | 12.11 | 28.08 | 11.77 | 26.77 | 799.48 | 15,604.18 |
Days of Inventory on Hand |
47.06 | 51.08 | 49.05 | 66.71 | 50.29 | 43.78 | 18.17 | 17.22 | 255.01 | 2,255.12 |
Average Receivables |
219.93 | 204.03 | 181.32 | 144.48 | 94.58 | 78.14 | 75.45 | 43.96 | 6.05 | 6.05 |
Average Payables |
7.30 | 6.31 | 6.09 | 3.84 | 7.10 | 8.13 | 9.20 | 8.92 | 7.40 | 6.32 |
Average Inventory |
38.24 | 33.95 | 39.42 | 31.95 | 16.50 | 12.63 | 8.73 | 4.82 | 1.56 | 1.56 |
Average Assets |
1,660.21 | 1,403.45 | 1,158.72 | 933.10 | 667.96 | 475.07 | 298.77 | 213.41 | 148.79 | 129.87 |
Average Common Equity |
265.26 | 212.14 | 195.14 | 198.89 | 194.48 | 136.73 | 89.51 | 97.83 | 119.49 | 109.99 |
Columns are period end dates